We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
UK drugmaker’s shingles vaccine boosts sales while demand for Covid-related products falls
Sebastien de La Riviere’s move is latest in a number of high-profile departures inside activist’s London office
A greater focus on innovation should top the UK pharma chief executive’s agenda
Chief commercial officer Luke Miels looking at targets worth up to $2.5bn
Judge rules that scientific evidence provided by the claimants was flawed
US judge dismisses almost 2,500 lawsuits alleging links between heartburn medication and cancer
UK pharma group will continue to lag rivals until litigation risk subsides
UK drugmaker beats forecasts and ‘expects good momentum in 2023’
Drugmaker says new RSV shot appears more effective than rival Pfizer’s candidate
Newly listed consumer health group refuses indemnification requests related to heartburn drug
Technology used to develop Covid vaccines may help in the fight against other diseases
Group developing jab with Sanofi that could have benefits
Pharma group alleges breach of non-compete agreement to delay start date of departing business development official
Investors should be wary of the damages a long, drawn out legal battle can inflict
Zantac makers feel the burn
Quarterly figures beat expectations as pharma group strengthens pipeline of new drugs
Investors cool on biggest London listing since Glencore in 2011 on worries about inflation and consumer confidence
Emma Walmsley believes listing of consumer health business will strengthen pharma division
Vote to separate consumer healthcare paves way for London’s largest stock market listing in a decade
Pharma companies are hoping to catch up with rivals as they report promising trial results for jab
‘Next-generation’ jab delivers strong immune response against variants
Successful trials for RSV vaccine add much-needed lift to the UK drugmaker’s pipeline
US pharma group to sell down stake in Haleon business after July IPO
Spinning off the business will make more bolt-on deals possible
UK drugmaker to pay $2.1bn upfront plus another potential $1.2bn as it boosts its vaccines business
International Edition
